ATLASATLAS fair value
DKK 337.35
Above fair value · 39% premium
Range: DKK 223–DKK 510Fair valuePrice
Novonesis (Novozymes) (NSIS-B.CO)
Novonesis (Novozymes) stock price today, ATLAS forecast and fair value
Basic Materials · Specialty Chemicals · Nasdaq Copenhagen · Denmark
DKK 469.00▲ +0.04%
Prices as of Oct 27, 2026 · DKK
Chance of rising in 1 month
51%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Novonesis (Novozymes) in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Novonesis (Novozymes)
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Novonesis (Novozymes)'s fair value at about DKK 337.35 per share (reasonable range: DKK 223.28 to DKK 509.69). At DKK 469.00, the stock trades 39% above it.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Novonesis (Novozymes) a 51% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between DKK 448.20 and DKK 493.33; in 9 out of 10, between DKK 411.66 and DKK 537.11. Estimated annual volatility is 29%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- DKK 216B
- Market cap (USD)
- $32.2B
- P/E ratio
- 45.8
- Dividend yield
- 0.19%
- 52-week high
- DKK 481.50
- 52-week low
- DKK 336.80
- Revenue (12 months)
- €4.3B
- Gross margin
- 56.4%
- Operating margin
- 23.4%
- Net margin
- 14.7%
- Beta
- 0.62
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Novonesis (Novozymes) sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks NSIS-B.CO has traded between DKK 336.80 and DKK 481.50. Today it is 2.6% below that high and 39% above its low.
On the business: net margin is 14.7%; it trades at 45.8 times earnings.
Its beta is 0.62: it tends to move less than the market.
About the company
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America.
Want to see everything about Novonesis (Novozymes)?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Novonesis (Novozymes) (NSIS-B.CO) fair value?
About DKK 337.35 per share according to ATLAS (reasonable range: DKK 223.28 to DKK 509.69). With the stock at DKK 469.00, it is 39% above it.
What is the chance NSIS-B.CO goes up next month?
51%: close to a coin flip. In half of the simulated outcomes, NSIS-B.CO ends the month between DKK 448.20 and DKK 493.33.
How big is Novonesis (Novozymes) and what is its P/E ratio?
Novonesis (Novozymes)'s market capitalization is DKK 216B. Its price-to-earnings (P/E) ratio is 45.8: you pay DKK 45.8 for each DKK 1.00 of yearly earnings.
Does Novonesis (Novozymes) pay a dividend?
Yes. NSIS-B.CO's current dividend yield is 0.19% at today's price (DKK 469.00).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer